Last Updated : May 13, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Spevigo | spesolimab | generalized pustular psoriasis (GPP) | Pending | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| Tafinlar-Mekinist | dabrafenib trametinib | Advanced or metastatic anaplastic thyroid cancer with BRAF V600E mutation | Pending | |||
| Vabysmo | faricimab | Retinal vein occlusion | Pending | |||
| N/A | nab-paclitaxel | Gastrointestinal cancer | Pending | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Pending | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Pending | |||
| TBC | fruquintinib | Metastatic colorectal cancer (mCRC) | Pending | |||
| Padcev | enfortumab vedotin | Metastatic urothelial cancer | Pending |
Last Updated : May 13, 2024